Roche ’s Elecsys IL-6 test receives FDA Emergency Use Authorisation to help in identifying patients at high risk of severe inflammatory response
             Basel, 04 June 2020   - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorisation (EUA) for the Elecsys® IL-6 test. This test measures levels of the biomarker interleukin 6 (IL-6) and can be used to help identify patients with confirm ed COVID-19 disease who could be at high risk of intubation with mechanical ventilation. The test can support physicians, in combination with other examinations and vital signs, to decide early on if a patient with confirmed COVID-19 illness requires mechanical ventilation. “The F...
Source: Roche Media News - June 4, 2020 Category: Pharmaceuticals Source Type: news

Roche initiates phase III clinical trial of Actemra/RoActemra plus remdesivir in hospitalised patients with severe COVID-19 pneumonia
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced the initiation of a global phase III, randomised, double-blind, multicentre study (REMDACTA) to evaluate the safety and efficacy of Actemra/RoActemra plus the investigational antiviral remdesivir, versus placebo plus remdesivir in hospitalised patients with severe COVID-19 pneumonia, in collaboration with Gilead Sciences, Inc. (Source: World Pharma News)
Source: World Pharma News - May 28, 2020 Category: Pharmaceuticals Tags: Featured Roche Business and Industry Source Type: news

Roche initiates phase III clinical trial of Actemra/RoActemra plus remdesivir in hospitalised patients with severe COVID-19 pneumonia
      ·Roche is also close to completing enrolment of a global randomised, double-blind, placebo-controlled phase III clinical trial of Actemra ®/RoActemra® (tocilizumab) in hospitalised patients with severe COVID-19 pneumonia (COVACTA), with results expected this summer. (Source: Roche Investor Update)
Source: Roche Investor Update - May 28, 2020 Category: Pharmaceuticals Source Type: news

Roche initiates phase III clinical trial of Actemra/RoActemra plus remdesivir in hospitalised patients with severe COVID-19 pneumonia
Basel, 28 May 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the initiation of a global phase III, randomised, double-blind, multicentre study (REMDACTA) to evaluate the safety and efficacy of Actemra/RoActemra plus the investigational antiviral remdesivir, versus placebo plus remdesivir in hospitalised patients with severe COVID-19 pneumonia, in collaboration with Gilead Sciences, Inc.   (Source: Roche Media News)
Source: Roche Media News - May 28, 2020 Category: Pharmaceuticals Source Type: news

Dilemma for doctors as Roche ’s experimental drug for Covid-19 is ‘life-saver’ but too costly
In India, the drug sold under the brand name Actemra, is approved for the use in autoimmune disease such as rheumatoid arthritis and for six months treatment it costs Rs 2.5 lakh. For Covid-19 patients who are administered this drug, the cost is Rs 60,000 per dosage. (Source: The Economic Times)
Source: The Economic Times - May 19, 2020 Category: Consumer Health News Source Type: news

Dilemma for doctors as Roche ’s Covid drug is ‘life-saver’ but too costly
In India, the drug sold under the brand name Actemra, is approved for the use in autoimmune disease such as rheumatoid arthritis and for six months treatment it costs Rs 2.5 lakh. For Covid-19 patients who are administered this drug, the cost is Rs 60,000 per dosage. (Source: The Economic Times)
Source: The Economic Times - May 19, 2020 Category: Consumer Health News Source Type: news

COVID-19 news from Annals of Internal Medicine
(American College of Physicians) Tocilizumab for Hemophagocytic Syndrome in a Kidney Transplant Recipient with COVID-19. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - May 18, 2020 Category: Infectious Diseases Source Type: news

Roche launches new blood gas digital solution designed to improve patient care
Basel, 15 May 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the CE mark availability of Roche v-TAC, a new digital diagnostic solution that allows clinicians to obtain results for arterial blood gas values from patients with respiratory or metabolic abnormalities via a simpler, less invasive venous puncture through the use of a digital algorithm. Blood gas analysis is typically used in hospital point of care (POC) settings, where quick and accurate results are needed. This includes emergency rooms, intensive care units and operating rooms. The analysis provides clinicians with information about a patient ’s p...
Source: Roche Investor Update - May 15, 2020 Category: Pharmaceuticals Source Type: news

Roche launches new blood gas digital solution designed to improve patient care
Basel, 15 May 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the CE mark availability of Roche v-TAC, a new digital diagnostic solution that allows clinicians to obtain results for arterial blood gas values from patients with respiratory or metabolic abnormalities via a simpler, less invasive venous puncture through the use of a digital algorithm. Blood gas analysis is typically used in hospital point of care (POC) settings, where quick and accurate results are needed. This includes emergency rooms, intensive care units and operating rooms. The analysis provides clinicians with information about a patient ’s p...
Source: Roche Media News - May 15, 2020 Category: Pharmaceuticals Source Type: news

Treating Covid-19: Clinical trials using arthritis drug get nod
“The CDSCO (Central Drugs Standard Control Organisation) has approved a vital randomised controlled trial on Covid-19 treatment with a biological called tocilizumab, in the first proposed multi-centre trial with the drug in India,” said Dr AS Soin, national lead investigator for the trial. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - May 11, 2020 Category: Pharmaceuticals Source Type: news

California doctor says arthritis drug improved coronavirus patients' symptoms within 72 hours
Dr Imran Sharief, a pulmonologist from Santa Ana California, gave tocilizumab, a drug used to treat rheumatoid arthritis, to severely ill coronavirus patients who were on ventilators. (Source: the Mail online | Health)
Source: the Mail online | Health - May 7, 2020 Category: Consumer Health News Source Type: news

Critically-ill coronavirus patient saved by quick-thinking doctor who gave him an arthritis drug
Dr Giorgio Gentile gave Leonard Whitehurst, being treated at Royal Cornwall Hospital, the drug tocilizumab as a last ditch attempt to save his life. He had heard promising results from early trials. (Source: the Mail online | Health)
Source: the Mail online | Health - May 4, 2020 Category: Consumer Health News Source Type: news

Yale Health System Keeps Updating Its COVID-19 Treatment Protocol Yale Health System Keeps Updating Its COVID-19 Treatment Protocol
Hydroxychloroquine is first-line, and tocilizumab second-line, for people with PCR – confirmed COVID-19. A multidisclipinary team is constantly monitoring the situation and making changes when needed.Medscape Medical News (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - May 1, 2020 Category: Drugs & Pharmacology Tags: Infectious Diseases News Source Type: news

Tocilizumab in Polyarticular Juvenile Idiopathic Arthritis Tocilizumab in Polyarticular Juvenile Idiopathic Arthritis
Is tocilizumab a safe and effective treatment option for polyarticular juvenile idiopathic arthritis?Rheumatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 1, 2020 Category: Consumer Health News Tags: Rheumatology Journal Article Source Type: news

Arthritis drug may prevent severely ill coronavirus patients from needing life support
A small French study has found that severely ill coronavirus patients given tocilizumab, a drug used to treat rheumatoid arthritis, were less likely to be put on life support and less likely to die. (Source: the Mail online | Health)
Source: the Mail online | Health - April 30, 2020 Category: Consumer Health News Source Type: news